eli lilli indianapoli sell new drug
loracarbef brand name lorabid broad-spectrum
treatment bronchiti pneumonia strep throat sinus-
middle-ear infect urinary-tract infect certain
skin infect includ impetigo fda offici describ
lorabid successor ceclor major eli lilli drug
put lot work develop drug said
bruce burlington fda offici 10,000 peopl
clinic trial much larger number usual
smithklin beecham share climb relafen
announc unlik word eli lilli
hoffmann-la roch approv came market close
friday london-bas smithklin american depositari
receipt close tuesday $ 86.25 $ 4 new york stock
exchang composit trade
relafen smithklin brand nabumeton one new
class non-steroid anti-inflammatori drug treatment
sever arthriti particular rheumatoid arthriti
osteoarthr 13 million peopl suffer arthriti
u.s. smithklin said current
15 non-steroid arthriti drug market
substanti differ demonstr
ulcer-caus potenti compani said
distinguish relafen non-acid
prodrug becom activ
pass stomach transform liver
said compani whose u.s. oper base
philadelphia
smithklin said control clinic trial
includ 1,677 patient treat relafen cumul
incid peptic ulcer 0.3 % three six month
0.5 % one year 0.8 % two year compani said
1,140 patient follow trial year
927 follow two year
relafen current market sever countri
world-wid sale $ 50 million u.s. market
includ analyst expect sale reach $ 200 million
1992
hoffmann-la roch plan market new drug
flumazenil brand name mazicon drug revers
sedat effect valium halcion drug
use anti-anxieti anti-depress therapi
part general anesthesia
first antidot valium
benzodiazepin overdos said robert templ senior
fda offici could provid
life support overdos fatal
particular drug taken along alcohol
hoffmann-la roch u.s. unit swiss drug maker roch
hold ltd. also make valium mazicon expect
wide use help anesthes patient wake
surgeri
fda commission david kessler approv 30 new
prescript drug 1991 seven previous
year agenc said also cut averag approv time
last year month take fda two
year approv new drug
late-decemb approv includ
simvastatin cholesterol-low drug merck
co. merck sharp dohm divis plan market zocor
pharmacolog similar anoth merck drug
lovastatin sold brand name mevacor
whether simvastatin advantag clear yet
said fda drug-review offici
cefprozil monohydr antibiot develop
bristol-my squibb co. treat mild-to-moder
respiratori infect well certain skin infect
compani market cefzil
isosorbid mononitr ismo drug made
american home product corp. wyeth-ayerst laboratori
prevent angina pectori due heart diseas
enoxacin warner-lambert co. drug treat
urinary-tract infect vener diseas gonorrhea
drug brand name penetrex similar other
market
